Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9967741 | 0.89 | TDP1 (0.58) | ALDH1A1HPGDMEN1KMT2APOLB | |
| SCHEMBL256087 | 0.86 | MEN1 (0.59) | ALDH1A1HPGDALOX15MEN1KMT2A | |
| SCHEMBL9967740 | 0.84 | SMN1; SMN2 (0.61) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL19016264 | 0.75 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2APOLBGAA | |
| SCHEMBL16638506 | 0.75 | L3MBTL1 (0.59) | ALDH1A1MEN1KMT2APOLBNPSR1 | |
| SCHEMBL10239972 | 0.75 | RORC (0.67) | ALDH1A1MEN1KMT2AGAAKDM4E | |
| SCHEMBL22793773 | 0.74 | ATM (0.68) | ALDH1A1HPGDALOX15MAPK1ATM | |
| SCHEMBL16638507 | 0.74 | L3MBTL1 (0.57) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL257065 | 0.74 | TDP1 (0.60) | ALDH1A1HPGDMEN1KMT2APOLB | |
| SCHEMBL16099017 | 0.74 | WNT3A (0.69) | ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | DHPS, FDPS, DPYD | ALDH1A1 333/4885HPGD 130/4885ALOX15 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.